BR0311128A - Pentafluorsulfanil-benzoilguanidinas, processo para a sua preparação, sua aplicação como medicamento ou diagnóstico bem como o medicamento contendo as mesmas - Google Patents

Pentafluorsulfanil-benzoilguanidinas, processo para a sua preparação, sua aplicação como medicamento ou diagnóstico bem como o medicamento contendo as mesmas

Info

Publication number
BR0311128A
BR0311128A BR0311128-8A BR0311128A BR0311128A BR 0311128 A BR0311128 A BR 0311128A BR 0311128 A BR0311128 A BR 0311128A BR 0311128 A BR0311128 A BR 0311128A
Authority
BR
Brazil
Prior art keywords
pentafluorsulfanyl
preparation
medicine
benzoylguanidines
diagnosis
Prior art date
Application number
BR0311128-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Heinz-Werner Kleemann
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0311128A publication Critical patent/BR0311128A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR0311128-8A 2002-05-18 2003-05-05 Pentafluorsulfanil-benzoilguanidinas, processo para a sua preparação, sua aplicação como medicamento ou diagnóstico bem como o medicamento contendo as mesmas BR0311128A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10222192A DE10222192A1 (de) 2002-05-18 2002-05-18 Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PCT/EP2003/004669 WO2003097591A1 (de) 2002-05-18 2003-05-05 Pentafluorsulfanyl-benzoylguanidine, verfahren zu ihrer hertellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament

Publications (1)

Publication Number Publication Date
BR0311128A true BR0311128A (pt) 2005-03-08

Family

ID=29285565

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311128-8A BR0311128A (pt) 2002-05-18 2003-05-05 Pentafluorsulfanil-benzoilguanidinas, processo para a sua preparação, sua aplicação como medicamento ou diagnóstico bem como o medicamento contendo as mesmas

Country Status (28)

Country Link
EP (1) EP1509498B1 (https=)
JP (1) JP4383341B2 (https=)
KR (1) KR100977676B1 (https=)
CN (1) CN100506791C (https=)
AR (1) AR040034A1 (https=)
AT (1) ATE343563T1 (https=)
AU (1) AU2003242531B2 (https=)
BR (1) BR0311128A (https=)
CA (1) CA2486336C (https=)
CY (1) CY1105867T1 (https=)
DE (2) DE10222192A1 (https=)
DK (1) DK1509498T3 (https=)
ES (1) ES2274264T3 (https=)
HR (1) HRP20041078B1 (https=)
IL (2) IL165213A0 (https=)
MA (1) MA27277A1 (https=)
ME (1) MEP28908A (https=)
MX (1) MXPA04011497A (https=)
MY (1) MY139310A (https=)
NO (1) NO333288B1 (https=)
PE (1) PE20040452A1 (https=)
PL (1) PL209700B1 (https=)
PT (1) PT1509498E (https=)
RS (1) RS50772B (https=)
RU (1) RU2315752C2 (https=)
TW (1) TWI281467B (https=)
WO (1) WO2003097591A1 (https=)
ZA (1) ZA200408886B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
DE10338554A1 (de) * 2003-08-22 2005-03-31 Aventis Pharma Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10353205A1 (de) * 2003-11-13 2005-06-16 Aventis Pharma Deutschland Gmbh Ortho-substituierte Pentafluorsulfuranyl-Benzole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als wertvolle Synthese-Zwischenstufen
DE10353204A1 (de) * 2003-11-13 2005-06-16 Aventis Pharma Deutschland Gmbh Verfahren zur Herstellung von 4-Pentafluorsulfanyl-benzoylguanidinen
OA13285A (en) * 2003-11-13 2007-01-31 Sanofi Aventis Deutschland Pentafluorosulfanyl benzoylguanidines, method for their production, their use as medicaments or diagnostic agents and medicament containing the same.
DE102004043938A1 (de) * 2004-09-11 2006-03-30 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE102004043937A1 (de) * 2004-09-11 2006-03-30 Sanofi-Aventis Deutschland Gmbh Ortho-substituierte Pentafluorsulfuranyl-Benzole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Synthese-Zwischenstufen
KR20110098012A (ko) * 2007-02-09 2011-08-31 화이자 리미티드 구충제
WO2008118787A1 (en) * 2007-03-23 2008-10-02 Im & T Research, Inc. Process for producing arylsulfur pentafluorides
WO2009028514A1 (ja) * 2007-08-28 2009-03-05 Ube Industries, Ltd. ペンタフルオロスルファニルベンゼン化合物の製造方法、及び新規なペンタフルオロスルファニルベンゼン化合物
RU2372331C1 (ru) * 2008-05-14 2009-11-10 Сергей Михайлович Игумнов СПОСОБ ПОЛУЧЕНИЯ ДИ(C1-C6 алкил)АМИНОТРИФТОРСУЛЬФУРАНОВ
JP5439745B2 (ja) * 2008-05-27 2014-03-12 宇部興産株式会社 ハロゲノメチルペンタフルオロスルファニルベンゼン化合物及びその製造方法
CN103974935B (zh) * 2011-12-06 2017-02-22 宇部兴产株式会社 五氟硫基苯甲酸的制造方法
CN108003034B (zh) * 2017-12-26 2020-07-03 金凯(辽宁)化工有限公司 一种2-甲基-5-氨基三氟甲苯的制备方法
RU2765117C2 (ru) * 2019-09-24 2022-01-25 Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" Применение натриевой соли диэтилового эфира 4-оксо-1,4-дигидропиразоло[5,1-с]-1,2,4-триазин-3,8-дикарбоновой кислоты, моногидрата в качестве средства лечения и профилактики поздних осложнений сахарного диабета

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4417004A1 (de) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19517848A1 (de) * 1995-05-16 1996-11-21 Merck Patent Gmbh Fluorhaltige Benzoylguanidine
DE19526381A1 (de) * 1995-07-19 1997-01-23 Hoechst Ag 4-Fluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9606015D0 (en) * 1996-03-22 1996-05-22 Rhone Poulenc Agriculture New herbicides

Also Published As

Publication number Publication date
NO333288B1 (no) 2013-04-29
ES2274264T3 (es) 2007-05-16
AR040034A1 (es) 2005-03-09
RS50772B (sr) 2010-08-31
AU2003242531A1 (en) 2003-12-02
KR100977676B1 (ko) 2010-08-25
CN1653044A (zh) 2005-08-10
CA2486336C (en) 2011-06-21
MXPA04011497A (es) 2005-02-14
NO20045447L (no) 2004-12-14
IL165213A0 (en) 2005-12-18
AU2003242531B2 (en) 2008-07-31
EP1509498A1 (de) 2005-03-02
JP4383341B2 (ja) 2009-12-16
RU2004137115A (ru) 2005-05-27
ATE343563T1 (de) 2006-11-15
CN100506791C (zh) 2009-07-01
PT1509498E (pt) 2007-01-31
RU2315752C2 (ru) 2008-01-27
DK1509498T3 (da) 2007-02-26
JP2005526138A (ja) 2005-09-02
ZA200408886B (en) 2006-01-25
CY1105867T1 (el) 2011-02-02
DE50305498D1 (de) 2006-12-07
EP1509498B1 (de) 2006-10-25
RS99004A (sr) 2007-04-10
KR20040111635A (ko) 2004-12-31
HK1076095A1 (zh) 2006-01-06
CA2486336A1 (en) 2003-11-27
HRP20041078A2 (en) 2005-04-30
PE20040452A1 (es) 2004-08-18
MA27277A1 (fr) 2005-04-01
PL371784A1 (en) 2005-06-27
WO2003097591A1 (de) 2003-11-27
PL209700B1 (pl) 2011-10-31
DE10222192A1 (de) 2003-11-27
TWI281467B (en) 2007-05-21
MY139310A (en) 2009-09-30
MEP28908A (en) 2010-10-10
IL165213A (en) 2009-05-04
HRP20041078B1 (hr) 2013-02-28
TW200407290A (en) 2004-05-16

Similar Documents

Publication Publication Date Title
BR0311128A (pt) Pentafluorsulfanil-benzoilguanidinas, processo para a sua preparação, sua aplicação como medicamento ou diagnóstico bem como o medicamento contendo as mesmas
BR0312697A (pt) Benzoiluréias substituìdas heterociclicamente, processo para a sua preparação e sua aplicação como medicamento
BR9911123A (pt) Derivados de dióxido de benzotiepina-1,1, processo para sua preparação, medicamentos contendo esses compostos e seu emprego
Zucker Effect of heparin on platelet function
EP2186795B1 (en) (1s, 2s, 3s, 4r)-3-ý(1s)-1-acetylamino-2-ethyl-butyl¨-4-guanidino-2- hydroxyl-cyclopentyl-1-carboxylic acid hydrates and pharmaceutical uses thereof
BR0316605A (pt) Derivados de fluorglicosìdeos aromáticos, medicamentos contendo estes compostos e sua aplicação
BR0315642A (pt) Antagonistas de cgrp selecionados, processo para sua preparação, bem como seu uso como medicamento
BR0009641A (pt) Derivados de 1,4-benzotiazepin-1,1-dióxido, substituìdos com radicais de açúcar, processo para produção dos mesmos, medicamentos contendo esses compostos e sua utilização
BR0013727A (pt) Derivados de sulfonilcarboxamida, processo para sua preparação e seu uso como medicamento
BR0307665A (pt) Compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades associadas com dpp iv e utilização dos compostos
BR0012138A (pt) Conjugado, composição que compreende conjugados, composição farmacêutica, utilização de um conjugado ou uma composição, processo para o tratamento profiládico e/ou terapêutico de distúrbios e processo para a preparação de um conjugado ou composição
BRPI0516842A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por lxr alfa e/ou lxr beta agonistas e uso desses compostos
BR0312702A (pt) Derivados de 3-guanidinocarbonil-1-heteroaril-pirrol, processo de preparação e intermediários desse processo, seu uso como medicamentos e composições farmacêuticas compreendendo os mesmos
BRPI0413798A (pt) benzoilguanidinas substituìdas por pentafluorsulfanilfenila, processo para sua preparação, seu emprego como medicamento ou diagnóstico, assim como medicamento contendo-as
BR0313188A (pt) Derivados de 3-guanidocarbonil-1-heteroaril-indol, processo de preparação, seu uso como medicamentos e composições farmacêuticas compreendendo os mesmos
BR0014233A (pt) Conjugados de 4-benzilaminoquinolina com ácido galênico e seus heteroanálogos, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação
EP0319676A2 (de) Chondroitinpolysulfat enthaltende Zusammensetzungen zur Behandlung von durch Retroviren verursachten immundefizienten Zuständen
BR0307495A (pt) Diidro-tia-fenantreno-carbonil-guanidinas, processo para sua preparação, seu uso como medicamento ou agente de diagnóstico
CY1106868T1 (el) Πενταφθοροσουλφανυλο-βενζοϋλογουανιδινες, μεθοδος για την παρασκευη τους, η χρηση τους ως φαρμακο ή διαγνωστικο μεσο, ως και φαρμακο που τις περιεχει
BR9800989A (pt) Benzoilguanidinas orto-substituìdas, processo para a sua preparação, seu uso como um medicamento ou diagnostico, e medicamento compreendendo as mesmas.
Coronary Drug Project Research Group Left ventricular hypertrophy patterns and prognosis: experience postinfarction in the Coronary Drug Project
BRPI0411343A (pt) derivados de 3-(guanidino carbonil) heterociclo, processo de preparação e intermediários deste processo, seu uso como medicamentos, e composições farmacêuticas incluindo os mesmos
Mollaamin et al. Drug delivery using doping of boron nitride nanosensor towards releasing chloroquine drug in the cells: A promising method for overcoming viral disease
Khandare et al. Study of cardiovascular complications and in hospital outcomes in patients of organophosphorus compound poisoning in tertiary care hospital.
BRPI0515148A (pt) benzoilguanidinas pentafluorsulfanilfenila-substituìdas, método para produção das mesmas, seu uso como medicamento ou agente de diagnóstico, e um medicamento contendo estes compostos

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.